Upgrade to SI Premium - Free Trial

Soligenix, Inc. (SNGX)

0.40 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/7/26)

Latest Headlines

Form 8-K SOLIGENIX, INC. For: Jun 10 June 12, 2026 4:07 PM - SEC Filing Soligenix applies for CEPI funding to develop Bundibugyo Ebola vaccine June 8, 2026 7:31 AM - StreetInsider Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine June 8, 2026 7:30 AM - PR NewsWire Form 8-K SOLIGENIX, INC. For: May 28 May 28, 2026 5:52 PM - SEC Filing Form 424B5 SOLIGENIX, INC. May 28, 2026 5:52 PM - SEC Filing Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo May 26, 2026 7:30 AM - PR NewsWire Form 424B3 SOLIGENIX, INC. May 8, 2026 4:17 PM - SEC Filing Form 424B3 SOLIGENIX, INC. May 8, 2026 4:14 PM - SEC Filing Form 424B3 SOLIGENIX, INC. May 8, 2026 4:13 PM - SEC Filing Form 424B3 SOLIGENIX, INC. May 8, 2026 4:12 PM - SEC Filing Form 10-Q SOLIGENIX, INC. For: Mar 31 May 8, 2026 4:06 PM - SEC Filing Soligenix Announces Recent Updates and First Quarter 2026 Financial Results May 8, 2026 7:30 AM - PR NewsWire Form 8-K SOLIGENIX, INC. For: Apr 28 April 28, 2026 7:30 AM - SEC Filing Soligenix halts Phase 3 trial of HyBryte for lymphoma treatment April 28, 2026 7:30 AM - StreetInsider Soligenix halts phase 3 trial of HyBryte for lymphoma treatment April 28, 2026 7:30 AM - StreetInsider Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma April 28, 2026 7:30 AM - PR NewsWire BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV April 10, 2026 10:00 AM - StreetInsider Form EFFECT SOLIGENIX, INC. April 3, 2026 6:04 AM - SEC Filing Form EFFECT SOLIGENIX, INC. April 3, 2026 6:04 AM - SEC Filing Form EFFECT SOLIGENIX, INC. April 3, 2026 6:04 AM - SEC Filing Form EFFECT SOLIGENIX, INC. April 3, 2026 6:04 AM - SEC Filing Soligenix publishes HyBryte study results in Oncology and Therapy April 2, 2026 7:30 AM - StreetInsider Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy April 2, 2026 7:30 AM - PR NewsWire Form POS AM SOLIGENIX, INC. March 31, 2026 4:15 PM - SEC Filing Form POS AM SOLIGENIX, INC. March 31, 2026 4:12 PM - SEC Filing Form POS AM SOLIGENIX, INC. March 31, 2026 4:11 PM - SEC Filing Form POS AM SOLIGENIX, INC. March 31, 2026 4:10 PM - SEC Filing Form 10-K SOLIGENIX, INC. For: Dec 31 March 31, 2026 4:07 PM - SEC Filing Soligenix reports $11.1 million net loss for 2025, cash at $7.9 million March 31, 2026 7:32 AM - StreetInsider Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results March 31, 2026 7:30 AM - PR NewsWire Soligenix receives EU orphan drug status for Behçet's disease treatment March 26, 2026 7:31 AM - StreetInsider Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease March 26, 2026 7:30 AM - PR NewsWire HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 March 23, 2026 7:30 AM - PR NewsWire Full Article List